The Oxford spinout has lured funding from OSI and the university itself as it aims to meet performance milestones for its peptide drug discovery programs.

UCLA's Magnify is looking for more local startups to join the 21 companies it currently supports, 80% of which operate in the life science sector.

Pfizer Ventures and Merck GHI both contributed to the cancer care technology provider's series B round, taking its overall funding to at least $38m.

Tel Aviv University’s TTO has set up a business called Nemis Technologies in partnership with BioSynth to develop pathological bacteria detection technologies powered by chemiluminescence.

Fidelity-backed medical access service Heal has now secured more than $69m in funding over the past four years.

GV and Blue Cross and Blue Shield Association are set to exit care provider Aspire Health following an acquisition agreement with Anthem.

Medicine development startup Brii Biosciences has launched with funding from investors including the WuXi AppTec-backed 6 Dimensions Capital.

Newly-launched ULB oncology spinout Epics Therapeutics will aim to develop drugs targeting malignant epigenetic RNA modifications.